Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
Breast Neoplasms|Neoplasm Metastasis
DRUG: everolimus (RAD001)
To establish the feasible dose levels/regimens based on End-of-cycle-1 dose limiting toxicity (DLT), after ever DLT within the first cycle, at least 21 days on treatment, every 2 months from first date of enrollment in a particular regimen
To assess the ability to deliver the trastuzumab and vinorelbine therapy, After LPLV|To assess everolimus, trastuzumab and vinorelbine blood levels in this combination, After LPLV|To evaluate the overall tumor response, every 9 weeks/minus 1 week
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.